KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31
Karyopharm Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.35−0.04 (-11.30%)
Close on Oct 19, 2026
- Market cap
- $10.01K
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-62.1%+96.9 pts over 5 years
Net margin
-134.2%+47.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +0.6% | -2.4% | +6.2% | +89.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -60.8% | -391.3% | 81.9% | |
| Return on assets | -55.4% | -64.6% | -143.7% | |
| Current ratio | 7.99 | 4.59 | 1.12 | |
| Interest coverage | – | -6.3× | -2.0× | |
| Capex to revenue | 45.5% | 0.1% | 0.0% | |
| Diluted shares | 3M | 5M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Karyopharm Therapeutics generated $552.25M from operations and spent $472.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$552.25M
Used
$472.00K
Capital expenditure$472.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-134.2%
×Asset turnover1.07×
×Equity multiplier-0.57×
=Return on equity, FY202581.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -134.2% | 1.07× | -0.57× | 81.9% |
| FY2024 | -52.6% | 0.72× | -1.26× | 47.4% |
| FY2023 | -98.0% | 0.49× | -3.92× | 187.2% |
| FY2022 | -105.2% | 0.47× | -6.89× | 343.2% |
| FY2021 | -59.1% | 0.68× | -21.23× | 852.0% |
| FY2020 | -181.6% | 0.36× | 6.06× | -391.3% |
| FY2019 | -488.1% | 0.13× | 2.73× | -171.4% |
| FY2018 | -588.1% | 0.12× | 1.67× | -114.1% |
| FY2017 | -8036.4% | 0.01× | 1.24× | -88.4% |
| FY2016 | -71153.9% | 0.00× | 1.10× | -60.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$196.04M
- Cash generatingOperating cash flow above zero-$75.37M
- Return on assets improvedROA up on the prior year-31.8% → -119.2%
- Earnings backed by cashOperating cash flow above net income-$75.37M vs -$196.04M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.70 → 1.12
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.60 → 0.89